Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer

Journal of Clinical Oncology - United States
doi 10.1200/jco.2012.44.5015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

Breast Care
SurgeryOncology
2008English

ERR Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy

Clinical Cancer Research
Cancer ResearchOncology
2009English

Cognitive Function in Postmenopausal Breast Cancer Patients One Year After Completing Adjuvant Endocrine Therapy With Letrozole and/or Tamoxifen in the BIG 1-98 Trial

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Tamoxifen — No Longer a Golden Standard for Adjuvant Therapy in the Treatment of Premenopausal Patients With Hormone-Sensitive Breast Cancer

Nowotwory
Cancer ResearchOncology
2017English

Mammographic Density ‘Unrelated to Breast Cancer Death Risk’

Springer Healthcare News
2012English

Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms

Oncology Nursing Forum
Oncology
2014English

Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Using Mammographic Density to Improve Breast Cancer Screening Outcomes

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy